Skip to main content

Advertisement

SpringerLink
Log in

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Mille PD (1999) Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352

    Article  PubMed  CAS  Google Scholar 

  2. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91

    Article  PubMed  CAS  Google Scholar 

  3. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 4:488–492

    Google Scholar 

  4. Aggart HT, Bolognese MA, Lindsay R, Ettinger MP, Mulder HF, Josse RG, Roberts A, Zippel H, Adami SV, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262–270

    Article  Google Scholar 

  5. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288–298

    Article  PubMed  CAS  Google Scholar 

  6. Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 171:998–1004

    Article  PubMed  Google Scholar 

  7. Ito M, Ikeda K, Nishiguchi M, Shindo H, Uetani M, Hosoi T, Orimo H (2005) Multi-detector row CT imaging of vertebral microstructure for evaluation fracture risk. J Bone Miner Res 20:1828–1836

    Article  PubMed  Google Scholar 

  8. Ivanovich P, Fellows H, Rich C (1967) The absorption of calcium carbonate. Ann Intern Med 66:917–923

    PubMed  CAS  Google Scholar 

  9. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS (1987) Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 317:532–536

    Google Scholar 

  10. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    Article  PubMed  CAS  Google Scholar 

  11. Colina RE, Smith M, Kikendall JW, Wong RK (1997) A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 92:704–706

    PubMed  CAS  Google Scholar 

  12. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–525

    Article  PubMed  CAS  Google Scholar 

  13. Leslie WD, Tsang JF, Caetano PA, Lix LM (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81

    Article  PubMed  CAS  Google Scholar 

  14. Fleisch H (1981) Biphosphonate: history and mechanism of action. Metab Bone Dis Rel Res 3:279–287

    Article  CAS  Google Scholar 

Download references

Conflict of interest

No benefit of any kind will be received either directly or indirectly by the authors.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, Suginami-ku, Tokyo, 166-8588, Japan

    Soichiro Itoh & Yohichi Sekino

  2. Department of Inorganic Materials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo, 101-0062, Japan

    Soichiro Itoh

  3. Department of Orthopaedic Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Ken-ichi Shinomiya

  4. Section of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Keio University, Shinanomachi 35, Shinjyuku-ku, Tokyo, 160-8582, Japan

    Shu Takeda

Authors
  1. Soichiro Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yohichi Sekino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken-ichi Shinomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Soichiro Itoh or Shu Takeda.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 72 kb)

About this article

Cite this article

Itoh, S., Sekino, Y., Shinomiya, Ki. et al. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 31, 206–211 (2013). https://doi.org/10.1007/s00774-012-0406-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-012-0406-9

Keywords

Search

Navigation